key: cord-0073108-mpn9mqp8
authors: Arévalos, Victor; Ortega-Paz, Luis; Brugaletta, Salvatore
title: Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes
date: 2022-01-07
journal: Med Clin (Engl Ed)
DOI: 10.1016/j.medcle.2021.05.008
sha: c7d0ea3a56566029d0042e508e2bbbc9a8c33bbc
doc_id: 73108
cord_uid: mpn9mqp8

nan

difference was driven by a higher risk of in-hospital all-cause death (13.9% vs. 1.6%, un-adjusted HR: 9.10 [95% CI 3.34-24.80], p = 0.001), with no differences in post-discharge risk of all-cause death between patients with or without COVID-19 (2.1% [11/534] vs. 2.5% [6/241], un-adjusted HR: 0.85 [95% CI 0.31-2.28], p = 0.739). Furthermore, at 6-month follow-up, cardiovascular death and PE rates were higher in COVID-19 patients than those without. Nevertheless, these differences were due to a higher rate of in-hospital cardiovascular death (2.3% vs. 0%, p = 0.018) and PE (3.4% vs. 0%; p = 0.001), without differences in the post-discharge follow-up. The in-hospital ACS rate was higher in patients with COVID-19 than those without (3.4% vs. 0.4%, p = 0.008). At 6-month, there were no differences in ACS between patients with or without COVID-19. Ultimately, there were no differences in stroke or HFH (Fig. 1B) .

At 6-month follow-up, we found a higher risk of all-cause death in COVID-19 patients. However, the difference between the groups was driven by a higher in-hospital all-cause death risk, without an increased risk during the post-discharge follow-up. Our data suggest that COVID-19 infection could be related to adverse acute cardiovascular outcomes without impaired outcomes beyond the disease's acute phase. Larger registries with extended follow-up must be performed to determine the long-term effect of COVID-19 on the cardiovascular system.

This study has been funded by Carlos III Institute, Madrid, Spain [Research grant COV20/00040].

Dear Editor,

We read with interest the publication in Medicina Clínica by Salman-Monte et al. 1 describing belimumab as a useful alternative therapy in systemic lupus erythematosus serositis (SLE). This research group have published satisfactory treatment response to belimumab for refractory pericarditis 1 and pleuritis 2 in SLE who fulfilled 1982 American College of Rheumatology criteria for SLE. 3 Mainly, SLE patients who develop refractory serositis may show short or long-standing SLE course. Several immunosuppressants (methotrexate, hydroxychloroquine, leflunomide along with lowmedium prednisone dosage; and aspirin for the pericarditis SLE patient) were prescribed to control other than serositis symptoms. Since majority of these SLE features are frequent and mild, though, the need to control patients' serositis symptoms, short of breath and serositis severity (massive pleuritis) made the authors try belimumab in order to control disease activity. Despite patients had previously failed to control disease activity through several treatments, belimumab showed both rapid efficacy and safety. Within a span of 6 months, both patients showed significant clinical improvement with no SLE flares and prednisone dosage was lowered. Altohugh several trials of belimumab have been performed in SLE, there is no specific data in serositis outcome, nor even in clinical practice. 4 We present a 29-year old woman with stablished SLE diagnosed in April 2018 with following ACR SLE criteria: malar rash, oral ulcers, photosensitivity, positive antinuclear antibodies (ANA) (1/640 titer) and anti-dsDNA antibodies testing. The patient also showed Raynaud's phenomenon hypocomplementaemia, positive RNP and Sm antibodies testing and polyarthralgia and fatigue. Initially, the patient responded to low-dose prednisone and hydroxychloroquine therapy. Patient also suffered from mild allergic asthma. In September 2019 the patient showed short of breath, chest pain, non-productive cough and a massive left pleuritis in the X-ray testing with an exudative pleural effusion evidence after performing diagnostic thoracocentesis. After com-mon respiratory and systemic infections and malignant, metabolic, cardiac and renal conditions were ruled out, patient initiated high-prednisone dosage and mycophenolate mophetil 720 mg daily, alongside hydroxychloroquine. Despite observing a moderate response after eight months of treatment, a moderate right pleuritis image in the routinely X-ray testing was demonstrated, higher anti-dsDNA level and worse hypocomplementaemia were present. Therefore, we considered mycophenolate mophetil as insufficient to control SLE activity (SLEDAI = 8) and subcutaneous belimumab was started. Since belimumab was initiated, the patient showed slow but evident improvement (negativization of anti-dsDNA levels, normalization of complement levels, significant X-ray and clinical improvement), allowing to reduce prednisone to 5 mg daily and stop mycophenolate mophetil treatment within six months.

To the best of our knowledge, the case we present is the second pleuritis SLE patient who show positive outcome during belimumab treatment, and the third suffering serositis (pleuritis and/or pericarditis) as well. In our case, a bilateral involvement was seen after intensive immunosuppressant and prednisone therapy. The latter highlights the need to control the underlying disease as, despite receiving intensive immunosuppressant treatment, the patient showed worsening of her pulmonary SLE involvement and evidence of serological SLE flare. Belimumab offered an alternative to better control disease in our case and we suggest including 'serositis' to the spectrum of SLE treatable features with belilmumab when other more well-known immunosuppressants fail to control SLE activity.

COVID-19 and the cardiovascular system

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Elevated troponin in patients with coronavirus disease 2019: possible mechanisms

Coronavirus disease 2019 -associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management

Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document

Victor Arévalos 1 , Luis Ortega-Paz 1 , Salvatore Brugaletta * Clinic Cardiovascular Institute, Department of Cardiology

Belimumab, a useful alternative therapy in systemic lupus erythematosus serositis

Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab

The 1982 revised criteria for the classification of systemic lupus erythematosus

The authors do not have conflict of interest for this study.